U.S., Dec. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07300943) titled 'Study in Advanced Solid Tumor Patients' on Dec. 14.
Brief Summary: The study will be conducted in 2 phases: Phase 1: Dose-escalation and Dose Level Expansion, Phase 1 will determine the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE). Phase 2: Tumor-Specific Expansions with Dose Optimization, Phase 2 will further evaluate CLIO-8221 in tumor-specific expansion cohorts to optimize dosing and assess preliminary efficacy.
Study Start Date: Feb. 28, 2026
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumor
Intervention:
DRUG: CLIO-8221
intravenous (IV) infusion
Recruitment Status: NOT_YET_RECRUITING...